FDA finalized "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" in late June 2025, superseding the 2023 version. The change that matters is a new section built directly around Section 524B of the FD&C Act.

For a cyber device, the submission is now expected to carry the statutory package: a secure product development framework and risk management, a machine-readable SBOM, and a plan to monitor, identify and address postmarket vulnerabilities, including coordinated disclosure and a patching path. 524B has been law since March 2023. What changed is that the expectations read like a checklist a reviewer can hold your submission against.

Miss a piece and it comes back as a deficiency, which is weeks you did not budget. Build the submission to the 2025 structure. The guidance is the closest thing to an answer key FDA publishes.